How Analysts Feel About XBiotech Inc. (XBIT) After Today’s Big Increase?

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock increased 16.30% or $1.18 during the last trading session, reaching $8.42. About 450,121 shares traded or 379.90% up from the average. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since February 5, 2018 and is downtrending. It has underperformed by 7.38% the S&P500.
The move comes after 6 months positive chart setup for the $301.60 million company. It was reported on Feb, 5 by Barchart.com. We have $9.09 PT which if reached, will make NASDAQ:XBIT worth $24.13M more.

More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “Subcutaneous formulation of XBiotech’s bermekimab successful in mid-stage study – Seeking Alpha” on January 23, 2019, also Seekingalpha.com with their article: “Bounce/Lag Momentum – Winning Stocks In A Market Downturn – Seeking Alpha” published on December 23, 2018, Nasdaq.com published: “XBiotech’s Results from Phase 2 Atopic Dermatitis Study Suggest New Drug to Treat Skin Disease – Nasdaq” on December 12, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Globenewswire.com and their article: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” published on December 03, 2018 as well as Nasdaq.com‘s news article titled: “Dr. Alice Gottlieb to Present Hidradenitis Suppurativa Findings at American Academy of Dermatology Annual Meeting – Nasdaq” with publication date: January 28, 2019.

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $301.60 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.

– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *